| Additional prognostic value of bone marrow histology in patients subclassified according to the International Prognostic Scoring System for myelodysplastic syndromes. | |
| | |
MedLine Citation:
|
PMID: 12525519 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
PURPOSE: The most recent and powerful prognostic instrument established for myelodysplastic syndromes (MDS) is the International Prognostic Scoring System (IPSS), which is primarily based on medullary blast cell count, number of cytopenias, and cytogenetics. Although this prognostic system has substantial predictive power in MDS, further refinement is necessary, especially as far as lower-risk patients are concerned. Histologic parameters, which have long proved to be associated with outcome, are promising candidates to improve the prognostic accuracy of the IPSS. Therefore, we assessed the additional predictive power of the presence of abnormally localized immature precursors (ALIPs) and CD34 immunoreactivity in bone marrow (BM) biopsies of MDS patients. PATIENTS AND METHODS: Cytogenetic, morphologic, and clinical data of 184 MDS patients, all from a single institution, were collected, with special emphasis on the determinants of the IPSS score. BM biopsies of 173 patients were analyzed for the presence of ALIP, and CD34 immunoreactivity was assessable in 119 patients. Forty-nine patients received intensive therapy. RESULTS: The presence of ALIP and CD34 immunoreactivity significantly improved the prognostic value of the IPSS, with respect to overall as well as leukemia-free survival, in particular within the lower-risk categories. In contrast to the IPSS, both histologic parameters also were predictive of outcome within the group of intensively treated MDS patients. CONCLUSION: Our data confirm the importance of histopathologic evaluation in MDS and indicate that determining the presence of ALIP and an increase in CD34 immunostaining in addition to the IPSS score could lead to an improved prognostic subcategorization of MDS patients. |
| | |
Authors:
|
E Verburgh; R Achten; B Maes; A Hagemeijer; M Boogaerts; C De Wolf-Peeters; G Verhoef |
Related Documents
:
|
8136289 - Clonal chromosomal abnormalities in fanconi's anaemia: what do they really mean? 11376809 - Karyotype and age in acute myeloid leukemia. are they linked? 12038519 - Co-existence of thrombocytopenia and hyperleukocytosis ('critical period') as a risk fa... 9738779 - Diffuse plane xanthoma: clinicopathologic study of 8 cases. 10678699 - Large plaque parapsoriasis: clinical and genotypic correlations. 2332039 - Prognostic significance of secondary cytogenetic changes and nonspecific cross-reacting... 3728879 - Acrodermatitis chronica atrophicans--a spirochetosis. clinical and histopathological pi... 18759599 - The natural history of the chiari type i anomaly. 19635419 - Foot build registration system (fbrs) to evaluate foot posture: a reliability study wit... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Journal of clinical oncology : official journal of the American Society of Clinical Oncology Volume: 21 ISSN: 0732-183X ISO Abbreviation: J. Clin. Oncol. Publication Date: 2003 Jan |
Date Detail:
|
Created Date: 2003-01-14 Completed Date: 2003-02-04 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 8309333 Medline TA: J Clin Oncol Country: United States |
Other Details:
|
Languages: eng Pagination: 273-82 Citation Subset: IM |
Affiliation:
|
Department of Hematology, University Hospitals, University of Leuven, Leuven, Belgium. estelle.verburgh@uz.kuleuven.ac.be |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adolescent Adult Aged Aged, 80 and over Antigens, CD34 / metabolism Bone Marrow / metabolism, pathology* Child Cytogenetic Analysis Female Humans Immunoenzyme Techniques Karyotyping Male Middle Aged Myelodysplastic Syndromes / classification, diagnosis*, metabolism Neoplasm Staging Prognosis Risk Factors Survival Rate |
| Chemical | |
Reg. No./Substance:
|
0/Antigens, CD34 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Gro...
Next Document: Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or re...